Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma

Study Summary

The purpose of this study is to determine the effectiveness of nivolumab adjuvant immunotherapy compared to placebo in adults and pediatric participants after complete resection of Stage IIB/C melanoma with no evidence of disease (NED) who are at high risk for recurrence.

Conditions

Melanoma

Interventions / Drugs

Nivolumab Placebo

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment790 participants

Primary Completion—

Lead SponsorBristol-Myers Squibb

Data Retrieved2026-04-11 04:08:14.745755+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.